Inflammation-induced vasoconstrictorhyporeactivity is caused by oxidative stress  by Pleiner, Johannes et al.
BASIC SCIENCE
Inflammation-Induced Vasoconstrictor
Hyporeactivity Is Caused by Oxidative Stress
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OBJECTIVES We sought to determine the role of oxidative stress in the development of vascular
dysfunction in inflammation.
BACKGROUND Hyporeactivity to catecholamines and other vasoconstrictors is present in acute inflammation.
Because oxidative stress plays a significant role in inflammation, impaired responsiveness may
be overcome by anti-oxidants.
METHODS In randomized, double-blind, cross-over studies, forearm blood flow (FBF) responses to
norepinephrine (NE), angiotensin II (ANG II), and vasopressin (VP) were assessed before
and 4 h after induction of systemic inflammation by low doses of Escherichia coli endotoxin
(lipopolysaccharide [LPS], 20 IU/kg intravenously) or after placebo in healthy volunteers.
Furthermore, the effect of intra-arterial vitamin C (24 mg/min) or placebo on NE-induced
or ANG II-induced vasoconstriction was studied after LPS.
RESULTS Administration of LPS caused systemic and forearm vasodilation, increased white blood cell
count, elevated body temperature, and reduced vitamin C plasma concentrations. Lipopoly-
saccharide decreased the responses of FBF to NE by 59%, to ANG II by 25%, and to VP by
51% (n  9, p  0.05, all effects). Co-administration of vitamin C completely restored the
response to NE and to ANG II, which was comparable to that observed under baseline
conditions (n  8).
CONCLUSIONS E. coli-endotoxemia reduces FBF responsiveness to vasoconstrictors. The hyporeactivity can
be corrected by high doses of vitamin C, suggesting that oxidative stress may represent an
important target for inflammation-induced impaired vascular function. (J Am Coll Cardiol
2003;42:1656–62) © 2003 by the American College of Cardiology Foundation
Despite advances in treatment, sepsis is still associated with
high mortality (1). Persistent systemic vasodilation requires
administration of catecholamines to increase blood pressure
(BP) and perfuse tissues. Improvement of hypoperfusion in
sepsis is limited by hyporeactivity to exogenously adminis-
tered catecholamines such as norepinephrine (NE). In a
previous study, we demonstrated systemic and regional
vascular hyporeactivity to adrenoceptor agonists after ad-
See page 1663
ministration of low doses of Escherichia coli endotoxin in
humans (2). This adrenoceptor hyporesponsiveness was
detectable in the absence of increased nitric oxide (NO)
bioactivity. The mechanisms underlying this hyporeactivity
are unclear, but oxidative stress secondary to increased
production of reactive oxygen species (ROS) has been
implicated in animal experiments (3). Increased ROS gen-
eration is present in inflammation, and these highly reactive
species can inactivate biologic mediators, including cat-
echolamines (4). Furthermore it is not known if vascular
hyporesponsiveness extends to other vasoconstrictors during
acute systemic inflammation induced by E. coli endotoxin in
humans. The purpose of the present study was to test if the
vasoconstrictor potency of angiotensin II (ANG II) and
vasopressin (VP) is also reduced during inflammation, and if
endotoxin-associated hyporesponsiveness to vasoconstric-
tors can be restored by high doses of the anti-oxidant
vitamin C. Systemic inflammation was generated by admin-
istration of low doses of lipopolysaccharide (LPS) in healthy
volunteers (2,5,6), and forearm vascular function was stud-
ied using strain-gauge plethysmography.
METHODS
The study protocols were approved by the Ethics Commit-
tee of the University of Vienna and comply with the
Declaration of Helsinki, including current revisions and the
Good Clinical Practice guidelines.
Study population. Twenty-five healthy male subjects be-
tween 21 and 38 years of age, from whom informed consent
was obtained before enrollment, were included in one of
three protocols. Where indicated, subject randomization
was done after enrollment by a member of the Department
of Clinical Pharmacology not involved in the study. All
subjects were given a complete health examination (includ-
ing physical examination, electrocardiogram, and laboratory
screening) within 14 days before the first study day. All
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subjects were non-smokers and had no history or signs of
arterial hypertension, hypercholesterolemia, or other cardio-
vascular risk factors. All of the subjects claimed not to have
ingested any prescribed medications, or over-the-counter
drugs from two weeks before screening until the study was
complete. After an overnight fast, studies were conducted in
a quiet room with an ambient temperature of 22°C with full
resuscitation facilities.
Generation of systemic inflammation in vivo. Twenty
IU/kg body weight LPS (dose corresponding to 2 ng/kg;
National Reference Endotoxin, E. coli, U.S.P. United States
Pharmacopeia Convention Inc., Rockville, Maryland) was
administered intravenously as a bolus infusion to induce
acute inflammation. Injection of LPS to humans has been
established by other groups and at our institution as a model
for acute systemic inflammation (2,5,6). It has been dem-
onstrated that this dose of LPS impairs the vascular re-
sponses to adrenergic vasoconstrictors and endothelium-
dependent vasodilators, with maximum clinical effect and
vascular hyporeactivity approximately 4 h after LPS admin-
istration (2,6). The flu-like symptoms are mild and tran-
sient, and subjects can be discharged after approximately 8
to 10 h in good health. Blood for analysis of white blood cell
count was drawn at baseline and 4 h after LPS administra-
tion. Tympanic temperature (Thermoscan pro, Braun AG,
Germany) was measured at frequent intervals; electrocar-
diogram, pulse rate, and BP were recorded with an auto-
mated device (Hewlett Packard CMS patient monitor, Palo
Alto, California).
Forearm blood flow measurements. Forearm blood flow
(FBF) was measured as described previously (2,7). Briefly,
strain gauges were placed on the forearms and connected to
plethysmographs (EC-6, DE Hokanson Inc., Bellevue,
Washington) to measure changes in forearm volume in
response to inflation of venous congesting cuffs. Bilateral
plethysmography was used, expressing drug effects as the
ratio of blood flow in the intervention to the control arm
(2,8), where baseline ratio was defined as 100%. Wrist cuffs
were inflated to suprasystolic pressures during each mea-
surement to exclude circulation to the hands. Flow mea-
surements were recorded for 9 s at 30-s intervals during drug
infusion. Traces were analyzed using the NIVP3 software
(Version 5.25, DE Hokanson Inc.).
Effect of vasoconstrictors. In a double-blind study, vascu-
lar responses to NE, ANG II, and VP were measured in
nine subjects (27  5 years) on two different trial days. The
order of the two days was randomized. On one day LPS was
administered, and on the other day a placebo vehicle, with
a washout period of at least seven days. Vasoconstrictors
were administered intra-arterially on both trial days. The
sequence of the vasoconstrictors under study was random-
ized between subjects but remained identical within each
subject.
A fine-bore needle (27G needle Sterican, B. Braun,
Melsungen, Germany) was inserted into the brachial artery
of the non-dominant arm for infusion of the vasoconstric-
tors. After a 20-min resting period, baseline FBF measure-
ments were made in response to increasing intra-arterial
doses of NE (60, 120, 240 pmol/min; Arterenol, Aventis,
Strasbourg, France), ANG II (25, 50, 100 pmol/min;
Clinalfa, La¨ufelfingen, Switzerland), and VP (3.2, 6.4, 16
ng/min; Clinalfa). Each dose was infused for 5 min, and a
washout period established control blood flow between
drugs under study. After dose-response curves had been
constructed, a systemic intravenous bolus of LPS (20 IU/kg)
or placebo (0.9% NaCl) was given. The FBF responses to
vasoconstrictors were repeated 240 min later, as described
earlier.
Effects of vitamin C. Two separate studies were conducted
in 16 volunteers (26 3 years) to study the effect of vitamin
C, which followed a double-blind, randomized, cross-over
design with a washout period of at least seven days. In these
experiments, the order of the study days (LPS with or
without co-administration of vitamin C) was randomized.
In the first study (n  8), a dose-response curve of FBF to
NE (60, 120, 240 pmol/min) was constructed before and
4 h after LPS on two different trial days; 230 min after LPS,
subjects received a continuous intra-arterial infusion of
vitamin C (24 mg/min, Mayerhofer GmbH, Linz, Austria)
(9,10) or physiologic saline over 25 min on two different
days. The response of FBF to NE co-administered with
vitamin C or placebo was assessed 10 min after the start of
infusion.
In the second study (n  8), FBF measurements were
made in response to intra-arterial ANG II (25, 50, 100
pmol/min) before and 4 h after LPS on two different trial
days. Again, an intra-arterial infusion of vitamin C or
physiologic saline was administered 230 min after LPS, and
the response to ANG II co-administered with vitamin C or
placebo was assessed 10 min after the start of infusion, as
previously described. Plasma for quantification of vitamin C
levels (Hitachi 911, Roche, Basel, Switzerland) was col-
lected from the non-intervention arm at baseline and 4 and
8 h after LPS.
Control experiments. To study the direct effects of vita-
min C on NE-induced and ANG II-induced vasoconstric-
tion, control experiments with vitamin C alone, without
Abbreviations and Acronyms
ANG II  angiotensin II
ANOVA  analysis of variance
BP  blood pressure
FBF  forearm blood flow
LPS  lipopolysaccharide (E. coli endotoxin)
NE  norepinephrine
NO  nitric oxide
NOS  nitric oxide synthase
NOx  nitrite
O2.
  superoxide radicals
ROS  reactive oxygen species
VP  vasopressin
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previous LPS administration, were performed on an open-
label trial day in eight subjects. The schedule of this study
day was otherwise identical to that described previously.
Statistical analysis. All data sets were tested for normal
distribution by the Kolmogorov-Smirnov test. Data for
white blood cell count, vitamin C, and FBF were normally
distributed. Data for temperature, pulse rate and BP were
log-normal distributed and therefore log transformed, after
which they tested positive for normal distribution. Hemo-
dynamic and laboratory parameters were expressed as abso-
lute values or percent changes from baseline and compared
using Student paired or unpaired t test. The FBF was
expressed as ml/min/100 ml forearm volume. Period and
carry-over effects for the main outcome parameters were
assessed with Student t test or the Wilcoxon rank-sum test,
depending on data distribution. The effects of NE, ANG II,
and VP at baseline and after LPS or placebo administration
were assessed by analysis of variance for repeated measure-
ments (ANOVA), followed by Bonferroni corrected t tests,
using the Statistica software package (Release 5.0, StatSoft
Inc., Tulsa, Oklahoma). A value of p 0.05 was considered
statistically significant. Values are presented as means 
SEM unless indicated otherwise.
RESULTS
Systemic hemodynamics, resting FBF, and laboratory pa-
rameters were comparable between trial days at baseline (not
shown). There was no evidence of a period effect or
carry-over between the first and the second trial day in
cross-over experiments. All infusions were well tolerated,
and no adverse events were reported. After LPS, the
expected mild and transient flu-like symptoms occurred.
The LPS increased white blood cell count after 4 h (p 
0.05, Table 1), which was paralleled by a decrease in BP and
an increase in pulse rate (p 0.05, Table 1). Hemodynamic
parameters returned to baseline 8 h after LPS. Mean FBF
also increased significantly after LPS (p  0.01, Table 1).
Effects of vasoconstrictors after LPS. At baseline, NE,
ANG II, and VP caused a dose-dependent decrease in FBF
to 72  3%, 55  5%, and 79  3% of control values,
respectively (p  0.05, all drugs). Four hours after LPS
administration, responses to all vasoconstrictors were atten-
uated: NE reduced FBF to a maximum of 89  3%, ANG
II to 66  5%, and VP to 90  3% of control values (Fig.
1). The ANG II-induced vasoconstriction was, however,
reduced to a lesser extent compared with the other vaso-
constrictors (p  0.05). Administration of placebo had no
effect on the vasoconstrictors; FBF was reduced by NE to 70
 3%, by ANG II to 53  4%, and by VP to 75  3% of
control values, which was not different from baseline mea-
surements (Fig. 1, p  NS).
Effect of vitamin C on NE and ANG II responsiveness.
Norepinephrine decreased FBF by 25  3% at baseline,
which was attenuated after LPS to 8  10% (p  0.05).
This hyporeactivity was completely restored by co-
administration of vitamin C (Fig. 2). Angiotensin II de-
creased FBF by 34  6% at baseline and by 22  5% after
LPS (p  0.05). Again, co-infusion of vitamin C restored
the vasoconstrictor potency of ANG II (Fig. 3). Systemic
vitamin C concentrations decreased by 29% after LPS (p 
0.05) and increased approximately sixfold during local
administration of vitamin C in the contralateral arm (p 
0.001, Table 2). Vitamin C had no effect on systemic
hemodynamics, baseline FBF, or NE- or ANG II-induced
vasoconstriction in control experiments (Table 3).
DISCUSSION
We have demonstrated that vasoconstrictor hyporeactivity
during E. coli endotoxemia in humans is not specific for
adrenoceptor agonists but also occurs in response to ANG
II and VP. Further, this study provides evidence for a direct
link between endotoxemia with impaired vasoconstrictor
function and oxidative stress, because the response to NE
and ANG II was normalized by co-administration of the
anti-oxidant vitamin C. Oxidative stress with consumption
of anti-oxidants and inactivation of vasoconstrictors may
play a significant role in the development of hyporeactivity
to exogenous vasoconstrictors during endotoxemia. The
functional alterations underlying impaired vasoconstrictor
responsiveness are not fully understood so far. Overproduc-
tion of NO by the inducible isoform of the nitric oxide
synthase (NOS) has been well characterized in animal
experiments. Assessment of NO formation proves difficult
in vivo, because its half-life is very short. Indirect methods
are influenced by many confounding factors. Measurement
of nitrate and nitrite (NOx), the stable metabolites of NO in
blood and urine, has been repeatedly used (11). However,
the concentrations of NOx vary considerably even in healthy
subjects (12), and the source of NO cannot be derived.
Exhaled NO as a marker of airway NO production is of
limited value in predicting NO production in the peripheral
vascular bed during systemic inflammation. A change in
exhaled NO concentrations in endotoxin-challenged volun-
teers was not paralleled by alterations in systemic hemody-
namics (11).
In our model of systemic inflammation, we have not
detected increased NOS activity, either by NOS messenger
ribonucleic acid expression in leukocytes or increased re-
sponsiveness to NOS inhibitors (2). Consistent with this is
Table 1. Systemic Hemodynamics, Laboratory Parameters, and
Forearm Blood Flow
Baseline 4 h After LPS
Heart rate (beats/min) 63  2 80  2†
Systolic blood pressure (mm Hg) 127  2 122  3*
Diastolic blood pressure (mm Hg) 70  2 63  1†
Body temperature (°C) 36.3  0.1 37.8  0.1†
White blood cell count (G/l) 5.4  0.3 9.5  0.6†
Forearm blood flow (ml/min/100 ml) 3.9  0.1 5.0  0.2*
Data are pooled for 25 subjects and presented as means SEM. *p 0.05, †p 0.01
versus baseline (paired t test).
LPS  lipopolysaccharide.
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the lack of beneficial effects of NOS inhibitors in human
sepsis (3,13,14). NO may have a role in certain types of
bacterial sepsis in humans, particularly in the presence of
putrefaction (15).
Alternative vasoconstrictors have been proposed for the
treatment of systemic hyporeactivity in sepsis (16–20), and
we set out to measure vascular responses to ANG II and VP
accordingly. However, the vasoconstrictor potency of all
drugs under study was significantly decreased, which is in
accordance with previous animal studies (21–23). It has
been demonstrated that the final common pathway of the
vasoconstrictors, that is, increase of intracellular Ca2,
could be influenced by LPS directly (24,25) and reduce the
responsiveness to vasoconstrictors (26). However, there are
no data from human studies available so far on the role of
altered Ca2 handling and inflammation. In previous ex-
periments, we observed that LPS administration did not
alter the response to the NOS inhibitor N-monomethyl-L-
arginine (2), arguing against a major effect of LPS on the
vascular smooth muscle contractile apparatus in this exper-
imental model.
Hyporesponsiveness to NE during systemic inflammation
is a consistent finding in experimental studies (16,27,28)
and was confirmed in this setting. It has been suggested that
increased generation of ROS like superoxide radicals (O2.
)
in inflammation would exceed the capacity of the endoge-
nous anti-oxidant defense system with consumption of
anti-oxidants (14). As a corollary, a significant decrease in
circulating vitamin C concentrations was detectable in our
experiments. At present, there is no method available to
assess O2.
 formation in vivo in humans directly. However,
there is evidence that O2.
 can inactivate NE during
inflammation, as autoxidation of catecholamines could be
prevented by a superoxide dismutase mimetic, which me-
Figure 1. Forearm blood flow (FBF) dose–response curves to norepinephrine (NE, upper panel), angiotensin II (ANG II, middle panel), and vasopressin
(VP, lower panel) at baseline and after administration of LPS (closed symbols) or placebo (open symbols). The response to vasoconstrictors was attenuated
after LPS. The FBF ratio (intervention vs. control arm, baseline defined as 100%) is expressed as mean SEM. n 9; *p 0.05 between groups, repeated
measures ANOVA and Bonferroni corrected t tests.
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tabolizes O2.
 (3). Vitamin C is an effective scavenger of
reactive species at this high local concentration (29) and has
been used to assess the bioactivity of endogenous O2.
 in
biologic systems (30). In the present study vitamin C
restored hyporeactivity to NE and ANG II caused by LPS,
and had no effect on vascular reactivity in subjects not
exposed to LPS.
Likewise, hyporeactivity to ANG II after LPS was also
restored by vitamin C. There is evidence that the aromatic
tyrosine residue of ANG II can be modified by peroxyni-
trite, the product of the reaction of NO and O2.
 (31,32).
In animal experiments, peroxynitrite reduced the vasocon-
strictor effect of ANG II accordingly (31). Considering the
continuous flux of newly synthesized NO by the vascular
endothelium (2,9), it can be speculated that nitrosation and
inactivation of circulating ANG II could occur at sites with
excess O2.
 production. This is compatible with in vitro
data which demonstrate that vitamin C is an effective
quencher of O2.
 and also of peroxynitrite (33,34). The
chemical reaction between ANG II and ROS is more likely
to contribute to impaired reactivity than downregulation of
angiotensin receptors, which can be detected later in sepsis
(22). One would therefore expect that the efficacy of ANG
II is diminished further after longer periods of inflammation
than in our LPS model.
The results obtained for VP have to be interpreted with
caution, because VP exerts a biphasic response in the
forearm with vasodilation at higher doses (35). Neverthe-
less, these experiments demonstrate that VP is also subject
to reduced vasoconstrictor potency after LPS. The octapep-
tide VP also contains the aromatic tyrosine and phenylala-
nine residues, which may react with reactive oxygen or
nitrogen species rendering the peptide inactive. These
findings argue for a crucial role of the oxidative status in the
development of vasoconstrictor dysfunction in endotoxemia.
In sepsis, clinical trials have suggested that VP or ana-
logues restore BP in patients with catecholamine-resistant
septic shock (18–20). However, in these studies VP was
given to patients to whom NE had already been adminis-
Figure 2. Vasoconstriction to norepinephrine at baseline (open symbols)
and 4 h after LPS, with co-infusion of placebo (closed symbols, upper
panel) or vitamin C (closed symbols, lower panel) on two different study
days. The FBF ratio (intervention vs. control arm, baseline defined as
100%) is expressed as mean  SEM. n  8; *p  0.05 between groups,
repeated measures ANOVA and Bonferroni corrected t tests.
Figure 3. Vasoconstriction to angiotensin II at baseline (open symbols)
and 4 h after LPS, with co-infusion of placebo (closed symbols, upper
panel) or vitamin C (closed symbols, lower panel) on two different study
days. The FBF ratio (intervention vs. control arm, baseline defined as
100%) is expressed as mean  SEM. n  8; *p  0.05 between groups,
ANOVA and Bonferroni corrected t tests.
Table 2. Systemic Vitamin C Plasma Concentrations at Baseline
and 4 and 8 h After LPS
Vitamin C Concentration (mol/l)
Baseline LPS, 4 h LPS, 8 h
Vitamin C 63.5  7.4 356.2  23.3*† 176.5  19.5*†
Placebo 64.3  3.9 45.4  5.0* 68.4  9.9
Vitamin C (24 mg/min) or placebo was infused over 25 min into the brachial artery,
230 min after lipopolysaccharide (LPS) administration, on different study days. Data
are presented as means  SEM (n  16). *p  0.05 versus baseline (paired t test);
†p  0.05 between study days (unpaired t test).
LPS  lipopolysaccharide.
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tered, and it is not certain to what extent the response to VP
was dependent on background NE, rather than evidence of
preserved sensitivity to VP.
One possible limitation of this cross-over study is that the
results could be confounded by endotoxin tolerance, as seen
in vitro and in animal studies (36). In the present study and
in our previous study, however, no hemodynamic tolerance
to repeated administration of LPS was observed in healthy
volunteers when there was a minimum washout period of
seven days between LPS administrations (9). This might be
due in part to the rather low dose of LPS used compared
with animal and in vitro experiments. In humans, endotoxin
tolerance has been described in ex vivo stimulation of whole
blood early after previous systemic LPS administration (37)
or in veins after daily local instillation of high LPS doses
(28).
In summary, we have demonstrated that hyporeactivity to
vasoconstrictors during inflammation is not exclusive for
catecholamines and involves ANG II and VP in vivo.
Secondly, inflammation is associated with consumption of
anti-oxidants, and hyporeactivity to vasoconstrictors caused
by LPS can be reversed by high circulating concentrations of
vitamin C. These observations suggest that administration
of vitamin C might restore sensitivity to constrictors in
clinical endotoxemia.
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